Is 9926.HK up or down today?
9926.HK is down 0.19% today, last at 123.87. This stock moved -0.19% versus the prior close.
9926.HK · 9926.HK
9926.HK (9926.HK) is trading at 123.87, down 0.19% on the session. 9926.HK sits at the 50% mark of its 52-week range, carries a 14-day RSI of 42, and trades below its 50-day average. Over the past month it is down 5.22%.
Leading the coverage: “Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC” (Yahoo Finance, 5d ago). 9926.HK is -2.47% since story.
9926.HK trades on a trailing P/E of 15.2 and is running 5.43% behind the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
9926.HK is down 0.19% today, last at 123.87. This stock moved -0.19% versus the prior close.
Leading the coverage: “Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC” (Yahoo Finance, 5d ago). 9926.HK is -2.47% since story. Dominant story: Why Akeso (SEHK:9926) Is Up 6.8% After Ivonescimab Tops Key Cancer Rivals In Phase III Trials – And What's Next - simplywall.st (1 source, bullish) RSI is 42 — leaning bearish Price below 50-day average — short-term weakness Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (181 days) · Drag or scroll left for earlier dates
Why Akeso (SEHK:9926) Is Up 6.8% After Ivonescimab Tops Key Cancer Rivals In Phase III Trials – And What's Next - simplywall.st
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Akeso, Inc. (HKG:9926) Analysts Are Cutting Their Estimates: Here's What You Need To Know - simplywall.st
Akeso (SEHK:9926) Stock Revenue Builds But Losses Keep Valuation In Focus - webull.com
Akeso (SEHK:9926) Stock Revenue Builds But Losses Keep Valuation In Focus - simplywall.st